<DOC>
	<DOCNO>NCT02058810</DOCNO>
	<brief_summary>The pilot study aim compare result use new respirator ( OPTIFLOW TM-High-Flow-Machine ) Standard-Oxygen-Therapy stabilization patient hospitalize due acute heart failure . We expect faster effective stabilization acute cardial decompensation among patient High-Flow-machine . The study show whether use High-Flow-Therapy lead relevant improvement term objective clinical parameter heart failure like cardial-renal syndrome , change nt-pro-BNP , weight loss , change diameter inferior vena cava , term degree shortness breath decompensation , whether subjective clinical symptom like dyspnea quality life differ two group patient . The investigator see primary outcome study improvement cardial-renal syndrome sign effective stabilisation compare standard therapy . Furthermore , investigator expect quick decrease serum creatinine improvement creatinine clearance therapy High-Flow-Machine . In term secondary outcome study , investigator interest also compare e.g. , duration hospital stay , 90-day mortality , rehospitalisation within three month . Here , investigator expect quicker improvement subjective shortness breath patient treat use Hifh-Flow-Machine . Moreover , believe along individual subjective improvement ( quality life survey ) , patient experience quicker release hospital way , lead healthcare economic improvement among patient repeat hospitalization usually chronic problem . It also great interest u , whether biomarker BNP appropriate parameter determine fast stabilization patient whether degree improvement subjective dyspnea correlate time need patient stabilise .</brief_summary>
	<brief_title>Nasal High Flow Acute Hart Failure</brief_title>
	<detailed_description>Primary endpoint : Improvement cardiorenal syndrome type1 measure improvement creatine clearance Serum-Creatinin patient undergo High-Flow treatment . Secondary endpoint : Worsening cardiac insufficiency ( application catecholamine , need NIV , intubation , death ) Duration hospital stay ( day ) 90-day mortality Readmittance hospital within 3 month Intrathoracic bloodvolume hospital discharge Change dyspnea 3h , 6h , 24h &gt; VAS-0-100 ( visual analog scale ) Change diameter IVC ( inferior vena cava ) non-invasive parameter assess degree decompensation Change BNP ( hospital admission vs. discharge , 3 month ) Weight loss hospital Amount diuretic</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>patient acute heartfailure NYHA III und IV Patients wit respiratory insufficency indication mechanical ventilation Asthma bronchiale severe COPD cardiogenic shock ( RR persist &lt; 90mmHg systolic catecholamine application ) renal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>nasal high flow oxygen</keyword>
	<keyword>cardio-renal syndrom</keyword>
	<keyword>heartfailure</keyword>
</DOC>